Apalutamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60mg
Reference Brands: ERLEADA (USA/EU)
Category: Oncology Cancer Care
Apalutamide is a next-generation androgen receptor inhibitor used for the treatment of prostate cancer, including non-metastatic castration-resistant and metastatic castration-sensitive forms. It works by blocking the effects of androgens, hormones that promote the growth of prostate cancer cells. Administered orally, Apalutamide is often used in combination with androgen deprivation therapy (ADT). Erleada has become an important option in prolonging survival and delaying disease progression in prostate cancer patients. Apalutamide is available in Tablets and strengths such as 60mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Apalutamide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Apalutamide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Apalutamide is used for the treatment of prostate cancer, including non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer. It works by blocking androgen receptors, which prevents testosterone from stimulating the growth of cancer cells, helping to slow disease progression and improve patient outcomes.
Apalutamide is made from Apalutamide, a next-generation androgen receptor inhibitor that selectively binds to androgen receptors in prostate cancer cells to inhibit their activity.
The trade name of Apalutamide is Erleada.
Apalutamide (Erleada) is manufactured by Janssen Biotech, a division of Johnson & Johnson, and distributed globally under approved regulatory pathways.
The generic name of Apalutamide is Apalutamide.
The brand name of Apalutamide is Erleada.
Apalutamide is manufactured in the United States and Europe by Janssen Biotech under GMP-certified facilities.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
